TPST:NASDAQTempest Therapeutics, Inc. Analysis
Data as of 2026-05-05 - not real-time
$2.11
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Technical outlook: The 20‑day SMA sits below the 50‑day SMA and the price is hovering near a key support level, while the MACD line has just crossed above its signal, suggesting a tentative bullish signal in an otherwise bearish market context. RSI is in a neutral zone, but the stock is experiencing extremely high 30‑day volatility and a decreasing volume trend, and its beta is well above the market average, all of which point to short‑term price pressure.
Fundamental backdrop: Tempest remains a pre‑revenue, clinical‑stage biotech with negative earnings, cash burn, and a debt load that slightly exceeds its cash holdings. The price‑to‑book ratio is modest, yet there is no dividend and the balance sheet is thin. Recent material news – a partnership to advance TPST‑2003 and the acquisition of dual‑targeting CAR‑T assets – introduces potential upside catalysts, but the company’s financial fragility and early‑stage pipeline keep the overall risk profile high.
Fundamental backdrop: Tempest remains a pre‑revenue, clinical‑stage biotech with negative earnings, cash burn, and a debt load that slightly exceeds its cash holdings. The price‑to‑book ratio is modest, yet there is no dividend and the balance sheet is thin. Recent material news – a partnership to advance TPST‑2003 and the acquisition of dual‑targeting CAR‑T assets – introduces potential upside catalysts, but the company’s financial fragility and early‑stage pipeline keep the overall risk profile high.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price near technical support with bearish SMA alignment
- decreasing trading volume and elevated volatility
- absence of revenue and negative cash flow
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- partnership to advance TPST‑2003 for a registrational study
- acquisition of CAR‑T assets expanding the pipeline
- potential uplift from upcoming clinical data releases
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- high‑growth opportunity in oncology if pipeline candidates succeed
- moderate price‑to‑book valuation relative to assets
- strategic collaborations that could de‑risk development costs
Key Metrics & Analysis
Financial Health
P/E Ratio-1.7
ROE-203.63%
ROA-56.86%
Debt/Equity122.09
P/B Ratio1.6
Op. Cash Flow$-26820000
Free Cash Flow$-17585750
Industry P/E25.6
Technical Analysis
TrendBearish
RSI57.6
Support$1.54
Resistance$2.46
MA 20$1.92
MA 50$2.01
MA 200$5.55
MACDBullish
VolumeDecreasing
Fear & Greed Index90.59
Valuation
Target Price$11.00
Upside/Downside421.33%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.62
Volatility117.82%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.